# A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

> **NCT04856891** · PHASE3 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 94 (actual)

## Conditions studied

- Eosinophilic Duodenitis
- Eosinophilic Gastroenteritis

## Interventions

- **DRUG:** AK002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04856891
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-06-14
- **Final completion:** 2023-01-09
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856891, "A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04856891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*